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Adiponectin (APM1) is an adipocyte-derived peptide that
contributes to glucose, lipid, and energy homeostasis. We
assessed the genetic basis of plasma adiponectin in Hispan-
ic-American and African-American families enrolled
through the Insulin Resistance Atherosclerosis Study Fam-
ily Study. A 10-cM genome scan was performed in two
batches: an original set (set 1) consisting of 66 families (45
Hispanic American and 21 African American) and a repli-
cation set (set 2) consisting of 66 families (45 Hispanic
American and 21 African American). Adiponectin levels
were measured by radioimmunoassay in 1,727 individuals
from 131 of 132 families. Linkage analysis was carried out
in Hispanic Americans and African Americans separately in
set 1, set 2, and the pooled set (set 1 plus set 2), with and
without diabetic subjects. A major gene was mapped to
3q27 with a logarithm of odds (LOD) score of 8.21 in the
Hispanic-American sample. Ninety-six unrelated individu-
als were screened for polymorphisms in the APM1 gene,
and 18 single nucleotide polyporphisms (SNPs) were geno-
typed in the Hispanic-American sample. Plasma adiponec-
tin level was modestly associated with two SNPs and their
accompaning haplotypes. Incorporating each or both SNPs
in the linkage analysis, however, did not significantly re-
duce the LOD score. Therefore, a quantitative trait locus at
3q27, likely distinct from the APM1 gene, contributes to
the variation of plasma adiponectin levels in the Hispanic-
American population. Diabetes 55:1723–1730, 2006
P
lasma adiponectin is an adipocytokine produced
by fat cells; its concentration was found to be
negatively correlated with BMI, insulin resis-
tance, hyperinsulinemia, plasma triglyceride con-
centration, and fasting and postprandial plasma glucose
concentrations (1–3). Recent data provide evidence for
genetic modulation of adiponectin levels. Family studies
(4–6) have shown adiponectin to be heritable, with heri-
tabilities reported to be in the range of 40–70%. Genome-
wide linkage scans found evidence, or suggestive
evidence, of linkage on chromosomes 5p, 14p, 2p, 3q, 10p,
and 17p in a predominantly northern European ancestry
population (4); evidence for linkage on chromosome 9p
and tentative evidence of linkage on chromosomes 2p, 3q,
and 10p in the Pima Indian population (5); evidence of
linkage on chromosome 15p in Chinese and on 18p in
Japanese, as well as suggestive evidence of linkage on
chromosomes 3, 18, and 20 in Japanese (6); and evidence
of linkage on chromosome 3q in the Old Order Amish (7).
In this study, we assessed the genetic basis of plasma
adiponectin in Hispanic-American and African-American
families. The genome scan study identified a major quan-
titative trait loci (QTLs) in Hispanic Americans but not in
African Americans in the region where the APM1 (ACDC)
gene is located. However, association analysis indicated
that the linkage signal could not be explained by the
assessed variation in the APM1 gene.
RESEARCH DESIGN AND METHODS
The Insulin Resistance and Atherosclerosis Study Family Study (IRASFS) was
designed to identify the genetic basis of glucose homeostasis and adiposity
traits. Details of the study design, recruitment, and phenotyping have been
described in detail (8). Briefly, large multigenerational African-American and
Hispanic-American families were recruited through probands of the parent
IRAS (9). Two-thirds (88) of the total 132 families were ascertained based on
a large family structure as reported in an IRAS family history interview, not on
clinical characteristics. Because the parent IRAS overrecruited people with
impaired glucose tolerance and type 2 diabetes, the prevalence of type 2
diabetes (28%) was higher in these probands than in the general population.
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The cohort was supplemented with 44 additional families from the community
and from ongoing research programs. The prevalence of type 2 diabetes was
also high in these probands (32%). Hispanic Americans were enrolled in San
Antonio, Texas, an urban Hispanic population, and San Luis Valley, Colorado,
a rural Hispanic population, and African Americans were enrolled in Los
Angeles, California. Institutional review board approval was obtained at each
collaborating institute. Informed consent was obtained from all subjects after
the procedures were explained.
Adiponectin assay. Plasma adiponectin levels were measured by radioim-
munoassay (Linco Research, St. Charles, MO) in 1,727 individuals (1,153
Hispanic Americans and 574 African Americans) from 131 IRASFS families (89
Hispanic American and 42 African American) for whom a 10-cM genome
scan had been completed (see below).
Microsatellite marker genotyping. A 10-cM genome scan using microsat-
ellite markers was conducted on 132 families of the IRASFS by the Mamma-
lian Genotyping Center in Marshfield, Wisconsin (available at http://
research.marshfieldclinic.org/genetics), in two separate batches. Set 1
consisted of 66 families (45 Hispanic American and 21 African American) with
988 individuals (674 Hispanic Americans and 314 African Americans), while
set 2 comprised 66 families (45 Hispanic American and 21 African American)
with 739 individuals (479 Hispanic Americans and 260 African Americans).
Adiponectin data were not available in one family. Mendelian inconsistency
was examined using the software PEDCHECK (10), and probable genotyping
errors were converted to missing. Pedigree relationships were confirmed
using the entire genome scan data (383 markers) and the software PREST
(11). Ninety-nine likely misspecified familial relationships were modified from
43 families. To account for possible founder effect, center-specific maximum
likelihood estimates of allele frequencies based on unrelated individuals were
obtained using the software LOKI (12–13) in the following linkage analyses.
Search for adiponectin polymorphisms. The APM1 gene maps to chromo-
some 3q27 and consists of three exons and two introns spanning 17 kb (14).
Several investigators have searched the APM1 gene for sequence variants and
have identified a range of variants located throughout the gene (14–16). We
have carried out an extensive search for additional variants in the proximal 5
promoter, coding sequence, and 3 untranslated region (UTR) sequence of the
APM1 gene using denaturing high-performance liquid chromatography. A total
of 96 DNA samples from unrelated African-American subjects were tested for
polymorphism screening (sequencing in African Americans should reveal the
most variation compared with that in Hispanics) (17). This search identified
two novel coding single nucleotide polymorphisms (SNPs): G113A (G38E) in
exon 2 and C1233T (Y111H) in exon 3 (previously observed in 16,18), in
addition to the previously described T45G (G15G), 13 SNPs in the long 3 UTR
sequence of the APM1 gene, and 3 promoter SNPs that had also been identified
in other laboratories (15–16). However, none of these 3 UTR SNPs fall within
known regulatory elements, e.g., AUUUA. The SNPs identified in the 3 region
were fairly close together and some had relatively low minor allele frequency;
thus, we chose only 2 polymorphic SNPs out of the 13 in the 3 UTR for further
genotyping. All three promoter SNPs were genotyped. In total, 18 SNPs (6
were identified by denaturing high-performance liquid chromatography in our
laboratory and 12 polymorphisms were identified through the National Center
for Biotechnology Information dbSNP database [available at http://
www.ncbi.nlm.nih.gov/SNP/and/or literature searches]) occurring in two link-
age disequilibrium (LD) blocks covering the entire APM1 gene (17) were
genotyped.
SNP genotyping. The 18 selected SNPs in the APM1 gene were genotyped in
the Hispanic-American sample using the Sequenom MassArray Genotyping
System (Sequenom, San Diego, CA). This genotyping system uses single base
extension reactions to create allele-specific products of SNPs that are readily
separated and automatically read by mass spectrometer in the MALDI-TOF
MassARRAY system (Bruker Daltonics, Billerica, MA). Fifty quality control
individuals were randomly placed throughout the plates and checked for
accuracy. Each SNP was examined for Mendelian consistencies using PED-
CHECK (10). Any genotypes inconsistent with Mendelian inheritance were
converted to missing.
Statistical analysis. Descriptive statistics were calculated for the study
sample. GEE1 (general estimating equations methods) (19) were used to test
for differences in adiponectin levels between men and women and between
Hispanic Americans and African Americans. To better approximate condi-
tional normality and homogeneity of variance, we examined a family of power
transformations, and natural log provided the best transformation for adi-
ponectin. However, modest departures from conditional normality may still
exist for log adiponectin, e.g., in the Hispanic-American sample, we observed
a skewness of 0.45 and kurtosis of 1.25 for the residuals of log(adiponectin)
after adjusting for age, sex, BMI, and clinic site. We therefore also obtained
empirical logarithm of odds (LOD) scores in our linkage analyses.
Linkage analysis. The variance component linkage analysis method, as
implemented in the Sequential Oligogenic Linkage Analysis Routines (SOLAR)
program, was used to test for evidence of linkage (20). In this approach, the
total variation in log(adiponectin) (2P) is partitioned into components of











Heritability (h2) is estimated by the proportion of total variation in adiponec-
tin levels due to genetic effects (h2  2G/
2
P). Similarly, the expected genetic
covariances between arbitrary relatives i and j can be specified as a function
of the identity by descent (IBD) and relationships at a given marker locus as
the following:
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where IBDij is the probability of individuals i and j share both alleles identical
by descent, ij is the corresponding kinship coefficient, and ij  1 if i  j and
0 otherwise. All results reported are based on multipoint estimates of the IBD
statistics. SOLAR tests for linkage by testing the null hypothesis that the
additive genetic variance due to a QTL equals zero (no linkage). Age, sex, BMI,
and center (in Hispanic-American sample) were all significant predictors for
adiponectin (P 	 0.01 each in the Hispanic-American sample), and the
proportion of total variance due to these covariates is 0.17. Therefore, all of
the four covariates were adjusted in the following analyses. Empirical P values
were generated by simulating a fully informative marker and gene dropping to
minimize any effect of departures from distributional assumptions using the
LODADJ option. These data were simulated and subsequent linkage analysis
computed 10,000 times to obtain the distribution of the test statistic under the
null hypothesis of no linkage. Given that this approach estimates a linear
correlation factor (21,22), 10,000 replications are a reasonable estimate. The
empirical P values were obtained as the proportion of the 10,000 replicates
that had an LOD score greater than or equal to the nominal LOD score that
was observed for the original linked locus. P values were converted to LOD
scores by LOD  
2/[2*ln (10)].
In set 1, we carried out a 10-cM genome scan linkage analysis for each
ethnic group (674 Hispanic-American individuals from 45 families resulting in
4,015 relative pairs including 694 full sibpairs; 314 African-American individ-
uals from 21 families resulting in 1,800 relative pairs including 243 full
sibpairs). The Hispanic-American set 2 sample was used for the confirmation
study, which comprised 479 individuals from 44 families (3,779 relative pairs
including 657 full sibpairs). The partitioning of the data into two samples
provides an opportunity to conduct a confirmatory analysis in regions
identified in the set 1 linkage analysis. To exclude the possible effect of
diabetes status on the linkage signal, the linkage analysis was repeated in the
Hispanic-American sample after excluding individuals with diabetes.
Association analysis. Two methods were utilized to test for an association
between individual SNPs in the APM1 gene and plasma adiponectin levels,
including the generalized estimating equations methods as described above
(19) and a variance components–based method as implemented in SOLAR.
Two degrees of freedom overall test of genotypic association and the three a
priori genetic models (i.e., additive, dominant, or recessive) when appropriate
were computed using generalized estimating equations methods as imple-
mented in the GENMOD procedure of SAS. In SOLAR association analysis, we
used dummy variables for each of the genetic models. A consistent finding of
association from both methods ensures to certain degree of reliability.
Haplotype analysis. As discussed in Sutton et al. (17), the level of LD among
the SNPs was estimated using the following equation:
D̂  
p̂11  p̂1p̂1
min ( p̂1p̂2, p̂1p̂2)
, D̂  0
p̂11  p̂1p̂1
min ( p̂1p̂1, p̂2p̂2)
, D̂ 	 0
, (3)
where for alleles 1 and 2 at the respective loci, D̂  p̂11  p̂1p̂1 is the classic
LD coefficient. Only the founders within the families were included in LD
analysis to eliminate bias due to family structure. Haplotypic association
analysis was then carried out using the quantitative pedigree disequilibrium
tests, using one, two, three, and four marker moving windows to assess
haplotype association (23).
Linkage analysis conditional on the SNPs in the APM1 gene. To evaluate
the contribution of the APM1 gene variations to the linkage signal, linkage
analyses were repeated in the Hispanic-American sample on chromosome 3
adjusting for each of the informative APM1 SNPs and/or combination of SNPs.
Specifically, SNP(s) was included as a covariate, assuming a dominant or an
additive model depends on the minor allele frequency. The percentage of
variance explained by SNP(s) was also estimated.
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RESULTS
Characteristics of the family cohort. Consistent with
the literature, mean plasma adiponectin levels were higher
in female than male subjects in both Hispanic Americans
([means  SD] 15.1  7.6 vs. 11.5  6.5 g/ml in the entire
Hispanic-American sample, 15.0  6.6 vs. 11.4  5.9 g/ml
in nondiabetic subjects, P 	 0.0001 for each) and in
African Americans (10.4  5.6 vs. 7.1  3.9 g/ml in the
entire African-American group, 10.5  5.0 vs. 7.0  3.8
g/ml in nondiabetic subjects, P 	 0.0001 for each) (Table
1). Interestingly, African Americans had significantly lower
mean adiponectin levels than Hispanic Americans in both
male (all individuals: 7.1  3.9 vs. 11.5  6.5 g/ml;
nondiabetic subjects: 7.0  3.8 vs. 11.4  5.9 g/ml, P 	
0.0001 for each) and female (all individuals: 10.4  5.6 vs.
15.1  7.6 g/ml, P 	 0.0001; nondiabetic subjects: 10.5 
5.0 vs. 15.0  6.6 g/ml, P  0.0003) subjects. Plasma
adiponectin levels were demonstrated to be highly herita-
ble with an estimated heritability of 0.71  0.06 in Hispanic
Americans after adjusting for age, sex, BMI, and center
and 0.64  0.08 in African Americans after adjusting for
age, sex, and BMI. When diabetic subjects were ex-
cluded, the heritability estimates increased to 0.84 
0.07 in Hispanic Americans and 0.82  0.09 in African
Americans.
Genome scan linkage analysis in set 1. Strong evidence
for linkage on chromosome 3q27 between markers
D3S2418 and MFD427 was observed in the Hispanic-
American sample (LOD  6.35 at 218 cM) and suggestive
evidence of linkage on chromosome 12 (LOD  2.18 at 111
cM between markers PAH and D12S2070) (Table 2). When
we further examined the chromosome 3 region by each
clinic site (San Antonio and San Luis Valley), we found
consistent evidences for linkage. In San Antonio alone, the
maximum LOD score was 3.22 observed at 217 cM, while
the maximum LOD score in San Luis Valley was 3.40,
occurring at 218 cM. However, no significant evidence of
linkage was observed in the African-American families
(LOD  0.0) in this region.
Confirmation linkage study in the Hispanic-American
sample. In the confirmation studies of the Hispanic-
American set 2 sample, which comprised 479 individuals
from 44 families (3,779 relative pairs including 657 full
sibpairs), an LOD score of 1.62 was observed in the same
region on chromosome 3, and the LOD score increased to
8.21 at 217 cM in the combined Hispanic-American sample
(set 1 plus set 2: 8,274 relative pairs including 1,432 full
sibpairs). The LOD-1 support interval surrounding the
Hispanic-American peak was between 213 and 222 cM (9
cM in length) between markers D3S2418 and MFD427. A
consistent linkage signal was again observed in San Anto-
nio (LOD  3.61 at 217 cM) and San Luis Valley (LOD 
4.64 at 218 cM) in the combined Hispanic-American sam-
ple. A new peak was identified on chromosome 7 (LOD 
2.68 at 132 cM between the markers D7S3061 and
D7S1804) in the Hispanic-American set 2 sample. In the
combined Hispanic-American sample, two additional re-
gions, chromosome 2 (LOD  2.48 at 207 cM, between
D2S1384 and D2S2944) and chromosome 12 (LOD  2.12
at 112 cM, between PAH and D12S395), showed suggestive
evidence of linkage. When excluding diabetic subjects, the
LOD score remained 5.98 on chromosome 3 at 218 cM and
2.09 on chromosome 2 at 199 cM. Interestingly, the maxi-
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(96 cM) to 2.21 (70 cM between D16S3396 and D16S3253).
Linkage analysis in the African-American sample. The
maximum LOD score on chromosome 3 was 0.63 at 131 cM
in the entire African-American sample, while the LOD
score at 218 cM, where the linkage peak was observed in
the Hispanic-American sample, was 0. The best evidence
of linkage in African Americans was on chromosome 10
(LOD  1.39 at 75 cM) between markers D10S1208 and
D10S1221, while no evidence of linkage was observed in
the Hispanic-American sample at this location.
The genome scan results are shown in Fig. 1 for
Hispanic-American set 1, Hispanic-American set 2, the
entire Hispanic-American sample, and the African-Ameri-
can sample. Figure 2 illustrates the detailed linkage results
for chromosome 3.
Empirical LOD scores. The empirical LOD scores are
also provided in Table 2. For the chromosome 3 peak, the
nominal LOD score remained as high as 5.82 at 217 cM in
the entire Hispanic-American sample and 4.60 at 218 cM in
the nondiabetic Hispanic-American sample. These analy-
ses further supported the existence of a QTLs on chromo-
some 3q27.
FIG. 1. Genome scan analysis of adiponectin
adjusted for age, sex, BMI, and center. Maxi-
mum LOD scores for chromosomes 1–22 are
presented as follows: Hispanic-American set
1, black lines; Hispanic-American set 2, red
lines; Hispanic-American sets 1 and 2, blue
lines; African Americans, green lines.
TABLE 2
Maximum LOD scores (position in cM) for plasma adiponectin levels*
Chromosome
HA Combined HA
(nondiabetic subjects) Combined AACombined Set 1 Set 2
2 Nominal 2.48 (207) 1.02 (202) 1.49 (207) 2.09 (199) 0.26 (266)
Empirical 1.76 (207) 0.74 (202) 1.47 (207) 1.61 (199) 0.28 (266)
3 Nominal 8.21 (217) 6.35 (218) 1.62 (228) 5.98 (218) 0.63 (131)
Empirical 5.82 (217) 4.64 (218) 1.60 (228) 4.60 (218) 0.68 (131)
7 Nominal 1.11 (81) 0.73 (80) 2.68 (132) 1.28 (82) 1.11 (107)
Empirical 0.78 (81) 0.53 (80) 2.63 (132) 0.99 (82) 1.20 (107)
10† Nominal 1.21 (152) 1.05 (151) 0.57 (164) 0.17 (154) 1.39 (75)
Empirical 0.86 (152) 0.77 (151) 0.56 (164) 0.13 (154) 1.49 (75)
12 Nominal 2.12 (112) 2.18 (111) 0.49 (166) 0.69 (135) 0.15 (70)
Empirical 1.50 (112) 1.59 (111) 0.48 (166) 0.53 (134) 0.16 (70)
16 Nominal 0.57 (96) 0.52 (114) 1.52 (66) 2.21 (70) 0.0 (0)
Empirical 0.40 (96) 0.38 (114) 1.49 (66) 1.70 (70) 0.0 (0)
*Those chromosomes that had a maximum LOD score 2.0 in Hispanic Americans (HA) are reported here. †The highest LOD score in African
Americans (AA).
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Association analysis for each SNP. Among the 18 SNPs
that were genotyped, 5 were found to be not polymorphic
(i.e., minor allele frequency was 	0.05) and were therefore
eliminated from further association analyses. The associ-
ation analysis of the 13 polymorphic SNPs in the APM1
structure gene revealed that only 2 SNPs, all located in the
5 promoter region, were associated with plasma adi-
ponectin levels: rs1656943 (P  0.003 from GENMOD and
0.03 from SOLAR) and G-11391A (P 	 0.0001 from GEN-
MOD and 0.01 from SOLAR) (Table 3). The minor allele in
each of the two SNPs was associated with increased
plasma adiponectin levels, as shown in Table 4.
Association analysis for haplotypes. Haplotype analy-
sis revealed that haplotypes in the genomic region be-
tween SNPs rs1656943 and G-11391A were associated with
adiponectin levels in the Hispanic-American sample. The P
value was 0.026 for haplotypes reconstructed using SNPs
rs1656943 and rs860291, while that for haplotypes recon-
structed using SNPs rs860291 and G-11391A was 0.002.
The three-SNP (rs1656943, rs860291, and G-11391A) hap-
lotype analysis yielded the most significant association
(P  0.001). The third most frequent haplotype carries the
rare variants at both rs1656943 and G-11391A and is
associated with elevated adiponectin levels (P  0.016),
FIG. 2. Linkage analysis of adiponectin on
chromosome 3 adjusted for age, sex, BMI, and
center. Maximum LOD scores on chromosome
3 are presented as follows: Hispanic-American
set 1, solid line; Hispanic-American set 2, dot-
ted line; Hispanic-American sets 1 and 2, dashed
line; African-American sets 1 and 2, dotted line.
TABLE 3
The SNPs in the APM1 gene and association analysis in the HA sample
SNP Gene region dbSNP Minor allele frequency P value GEE1 P value SOLAR
C-19148T Promoter rs4632532 0.45 0.91* 0.74
C-17760T Promoter rs6444169 0.18 0.45† 0.45
T-14816C Promoter rs1656943 0.05 0.003† 0.03
C-12896T Promoter rs860291 0.10 0.24† 0.18
G-11391A Promoter dHPLC 0.05 	0.0001† 0.011
C-11377G Promoter rs266729 0.31 0.70* 0.56
InsCA_11156 Promoter dHPLC 0.15 0.43† 0.64
A-10066G Intron1 rs182052 0.45 0.98* 0.84
G-7950T Intron1 rs822390 0.23 0.26† 0.13
A-4120C Intron1 rs822394 0.22 0.18† 0.06
T45G Exon2 rs2241766 0.18 0.78† 0.98
G276T Intron2 rs1501299 0.24 0.17† 0.17
A712G Intron2 rs3774261 0.44 0.82* 0.76
*General association model. †Dominant model. HA, Hispanic American.
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while the most frequent haplotype (111) is associated with
decreased adiponectin levels (P  0.005, Table 4).
Linkage analysis conditional on the SNPs and haplo-
types in the APM1 gene. To have a consistent sample
and to be able to compare the change in the LOD scores in
the models with and without the SNP adjustment, we
restricted the linkage analyses to those individuals with
genotypes available for the SNPs of interest. Adjusting
individually for each SNP did not change the maximum
LOD significantly: estimated scores reduced from 8.76 to
8.40 after adjusting for rs1656943 and from 8.59 to 8.23
after adjusting for G-11391A. Adjusting for these two SNPs
simultaneously reduced the LOD score from 9.11 to 8.70.
When adjusting for haplotypes for SNPs rs1656943,
rs860291, and G-11391A, the LOD score reduced from 8.19
to 7.17 (Table 4). This indicates that these SNPs are not
major determinants of the large linkage peak observed in
this study. Supporting this conclusion, the estimated per-
centage of adiponectin variation explained by the SNP(s)
and/or haplotypes was also quite low (Table 4).
DISCUSSION
The goal of this study was to elucidate the genetic basis of
plasma adiponectin in Hispanic-American and African-
American families. We performed a genome-wide scan of
plasma adiponectin levels in 89 Mexican-American and 42
African-American families including 1,727 individuals
(1,153 Hispanic Americans and 574 African Americans).
The initial linkage analysis carried out in the first half of
the sample revealed strong evidence for linkage on chro-
mosome 3q27 in the Hispanic-American sample. The con-
firmation study of the Hispanic-American set 2 sample
found an LOD score of 1.62 in the same region. The LOD
score increased to 8.21 in the combined Hispanic-Ameri-
can sample. Excluding diabetic subjects reduced the LOD
score to 5.98 but still established the existence of a QTL on
chromosome 3 near 218 cM, which excludes the possibility
of a false-positive due to possible influence of diabetes
status. The consistency of the linkage results, from set 1,
set 2, the combined Hispanic-American sample, and com-
bined Hispanic-American sample after excluding diabetic
subjects, is reassuring of the existence of a QTL on
chromosome 3q27.
Experimental data suggest that plasma adiponectin lev-
els might be one of the key molecules in the development
of the metabolic syndrome (24). Available genome-wide
scans have mapped a susceptibility locus for type 2
diabetes and aspects of the metabolic syndrome to the
same location, chromosome 3q27 (25–26). We therefore
investigated polymorphisms in the APM1 gene located at
3q27, using association and linkage analysis conditional on
SNPs and/or haplotypes as an explanation for the linkage
signal. Two SNPs (rs1656943 and G-11391A) in the 5
promoter region were found to be statistically associated
with plasma adiponectin levels, but they explained only a
very small amount of adiponectin variation, and adjusting
for each of the two SNPs or adjusting for both simulta-
neously in the linkage analysis did not change the LOD
score appreciably. These results indicate that the evidence
of linkage in our sample cannot be explained by the
assessed variation in the APM1 gene.
SNP 2019 delA, which was found to contribute to the
linkage of adiponectin levels in Amish individuals (7), was
not genotyped in this population. However, based on LD
data from Vasseur et al. (16), 2019 delA is in complete LD
with SNP A712G (D  0.99). Given the lack of association
with SNP A712G as well as haplotypes generated from the
region containing SNP A712G in the IRASFS participants
and the high LD between SNPs, it is unlikely association
would be identified with SNP 2019 delA. We also exam-
ined regions of high conservation among species (the
highest conservation was the coding regions and the
proximal 5 promoter), which was extensively screened.
There may be additional regulatory regions that we did not
identify and/or genotype. However, to the best of our
knowledge, little work has been functionally done to
determine the regulatory regions further up or down-
stream from APM1 that could be responsible for control-
ling APM1 levels. It should be noted that the next gene 5
to adiponectin (RFC4) is only 3.6 kb upstream from exon
1 of adiponectin and the next gene 3 (ST6GAL1) is only
7.2 kb away. There does not seem to be much room for
additional regulatory elements. The discrepant findings in
association with APM1 gene could be due to ethnic
differences or differences in SNPs genotyped. Also, the
functional SNP probably has yet to be identified in any
population; thus, different studies are detecting associa-
tion due to LD with the functional SNP, leading to different
SNP associations. Further efforts to investigate other
genes in the regions are underway.
BMI, body weight, and fasting insulin levels in Cauca-
sians (25) and early-onset diabetes in French Caucasians
(26) have been mapped to 3q27. Polymorphisms in the
APM1 gene have been reported to be associated with BMI,
insulin sensitivity, type 2 diabetes, coronary artery dis-
ease, and metabolic syndrome (15,27–28). To explore the
relationship among the APM1 gene, adiposity, and plasma
adiponectin levels, we examined the genetic correlation
TABLE 4
The mean adiponectin levels in the Hispanic-American sample classified by genotype of the two associated SNPs and by haplotypes,
P value for association, and SNP(s)/haplotype contributions to the linkage signal
SNP
Mean adiponectin (g/ml)
P value LOD score reduction Percent variance*1/1 1/2  2/2
rs1656943 13.31  6.90 (995) 14.99  7.20 (118) 0.003 8.76 3 8.40 0.16
G-11391A 13.29  6.88 (1,025) 15.80  7.43 (108) 	0.0001 8.59 3 8.23 0.17
Both SNPs — — — 9.11 3 8.70 0.17
Haplotypes (rs1656943, rs860291, and G-11391A) 0.001 8.19 3 7.17 0.18
Noncarriers Carriers
Haplotype 1 16.29  7.04 (58) 13.39  6.33 (1,094) 0.005 — —
Haplotype 3 13.32  6.32 (1,050) 15.82  6.72 (102) 0.016 — —
Data are means  SD (n), unless otherwise indicated. *0.17% variance was explained by age, sex, and BMI for samples being typed on one
of the three SNPs.
NOVEL MAJOR QTLs FOR PLASMA ADIPONECTIN
1728 DIABETES, VOL. 55, JUNE 2006
between BMI and adiponectin. A significant genetic corre-
lation was observed in the Hispanic-American sample
(0.22  0.09, P  0.016), while a modest genetic corre-
lation was observed in the African-American sample
(0.17  0.13, P  0.21). The evidence of the existence of
common gene(s) underlying adiponectin and BMI in the
Hispanic-American sample leads to the question of
whether the gene(s) affects adiponectin levels through
BMI or through a different mechanism. We therefore also
ran the multipoint linkage analysis in the combined His-
panic-American sample (set 1 plus set 2) for chromosome
3 without adjusting for BMI. A maximum LOD score of
8.18 was obtained at 218 cM compared with a maximum
LOD score of 8.21 at 217 after adjusting for BMI. The
gene(s) harbored in the 3q region appear to be affecting
plasma adiponectin level independently of BMI.
Differences were observed between Hispanic Americans
and African Americans within the IRAS families. First, the
levels of adiponectin were very different in these groups,
and this was not explained by BMI. Second, even though
the heritabilities were equivalent, the linkage results were
very different. In the 3q27 region, where we identified a
QTL in the Hispanic-American sample, no evidence of
linkage was observed in the African-American sample. We
also identified several regions that showed suggestive
evidence of linkage in the Hispanic-American sample,
including chromosomes 2, 7, and 12, but no evidence of
linkage was observed in the African-American sample in
any of these regions. The best evidence of linkage in
African Americans was on chromosome 10, while no
evidence of linkage was observed in the Hispanic-Ameri-
can samples at this location. The newly identified QTLs
location (3q) in the Hispanic-American samples of our
study is the same as in the Old Order Amish (7) but is
different from northern European (5p, 14p) (4), Pima
Indian (9p) (5), Chinese (15p) (6), and Japanese (6),
suggesting genetic heterogeneity among different popula-
tions. We also observed a higher heritability in both
Hispanic Americans (0.71) and African Americans (0.64)
compared with Caucasians and Pima Indians (40–45%).
Since adiponectin is present in plasma in multimeric forms
(29), the variation in laboratory approaches could account
for some of the large variation of heritability values seen in
various studies. However, there is no particular associa-
tion between observing a higher or lower heritability and
use of a specific method.
In conclusion, we have observed strong linkage evi-
dence for a QTL on chromosome 3q27, apparently distinct
from the APM1 gene, that contributes to the variation of
plasma adiponectin levels in the Hispanic-American pop-
ulation. Furthermore, ethnic-based genetic heterogeneity
that determines plasma adiponectin levels was evident.
Identifying genes in these regions should provide insight
into the regulation of adiponectin and its relation to insulin
sensitivity, obesity, and diabetes. This may facilitate the
development of more effective therapies for prevention
and treatment of diabetes and associated cardiovascular
diseases.
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